Science
    Obesity

    Obesity Is a Disease, Not a Choice: What the Science Says

    The idea that obesity is simply about eating too much and moving too little is decades out of date. Modern science tells a different story, one that changes how we think about treatment.

    Last updated: March 10, 202612 min read

    In 2013, the American Medical Association officially recognized obesity as a disease. Not a risk factor. Not a lifestyle choice. Not a personal failing. A disease. This was not a political statement. It was an acknowledgment of overwhelming scientific evidence showing that obesity involves complex biological mechanisms that go far beyond diet and exercise choices.

    Medical Disclaimer

    This article presents scientific and medical information about obesity. It is not medical advice. Consult a healthcare provider about your individual situation.

    The Biology of Obesity

    Biological Factors Driving Obesity

    • Genetics: Over 200 genes have been identified that influence body weight, appetite, metabolism, and fat storage. Twin studies show that BMI is 40-70% heritable.
    • Hormones: Leptin resistance, ghrelin dysregulation, insulin resistance, and cortisol elevation all promote weight gain independent of food choices.
    • Neurology: The brain's reward system and appetite centers are structurally and functionally different in people with obesity, driving stronger hunger signals and food-seeking behavior.
    • Gut microbiome: Differences in gut bacteria composition affect calorie extraction, inflammation, and appetite signaling.
    • Epigenetics: Environmental exposures (including in utero) can modify gene expression related to metabolism and fat storage for a lifetime.
    • Metabolic adaptation: The body actively defends against weight loss by reducing metabolic rate and increasing hunger hormones.

    Why Willpower Is Not the Answer

    Consider this: if obesity were truly about willpower, we would expect random distribution across populations and time periods. Instead, obesity rates have tripled in just 50 years while human willpower has not changed. This points to environmental and biological factors, not moral character.

    Research from the National Institutes of Health shows that the body responds to weight loss as a threat. When you lose weight through dieting alone, your body reduces your metabolic rate by 15 to 25 percent below what is predicted for your new size. It increases ghrelin (hunger hormone) by up to 20 percent. It decreases leptin (satiety hormone). And it alters brain chemistry to make food more rewarding. This is not a willpower problem. This is your biology fighting to restore what it perceives as normal weight. This is why 95% of diets fail within 5 years.

    How Obesity Meets Disease Criteria

    A disease is defined as an impairment of normal body function that results in detectable signs or symptoms. Obesity meets every criterion. It involves impaired function of appetite regulation, energy metabolism, and hormonal signaling. It produces measurable physiological changes (elevated blood sugar, blood pressure, inflammation markers). It increases the risk of serious health consequences (type 2 diabetes, heart disease, certain cancers, stroke). It responds to medical treatment. And it has a predictable clinical course if untreated.

    Why Medical Treatment Makes Sense

    When we accept that obesity is a disease with biological drivers, medical treatment becomes logical rather than controversial. GLP-1 medications work by correcting the hormonal and neurological dysfunction that drives obesity. They reduce the exaggerated hunger signals, restore a more normal appetite, and allow the body to lose weight without the extreme metabolic pushback that sabotages dieting.

    This is no different from treating diabetes with insulin, treating hypertension with blood pressure medication, or treating depression with antidepressants. No one questions whether a diabetic "should" take insulin. The same logic applies to treating obesity with GLP-1 medications.

    The Damage of Stigma

    Framing obesity as a personal choice causes measurable harm. Weight stigma leads people to avoid medical care, increases cortisol (which promotes further weight gain), worsens mental health, and paradoxically increases disordered eating. When patients internalize the belief that their weight is their fault, they are less likely to seek the medical treatment that could help them.

    Recognizing obesity as a disease removes the shame and replaces it with a clinical framework: diagnosis, treatment options, and monitoring. This is healthier for patients and produces better outcomes.

    The Bottom Line

    Obesity is a chronic disease with biological, genetic, hormonal, and neurological causes. It deserves the same evidence-based medical treatment we give to any other chronic disease. If you have struggled with weight loss despite genuine effort, know that the struggle is not a character flaw. It is your biology. And modern medicine, including GLP-1 medications, finally offers tools that work with your biology rather than against it.

    Treat Obesity Like the Disease It Is

    GLP-1 medications address the biology. Semaglutide $99/mo, tirzepatide $125/mo at Trimi.

    Explore Treatments

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: October 1, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    What to expect in your first month on retatrutide: realistic weight loss expectations, side effects, appetite changes, and tips for maximizing early results during the dose titration phase.

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    Start your GLP-1 journey — from $99/mo

    Get Started